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Each year approximately 15,000 patients are diagnosed with colorectal cancer (CRC) in the Netherlands, 
of whom 5–10% are associated with a hereditary syndrome. To enable future research into hereditary 
CRC, we established a collaborative biobank for hereditary CRC in all eight University Medical Centers 
(UMCs) in the Netherlands in 2009. This Biobank Hereditary CRC is part of the Parelsnoer Institute (PSI), 
which is funded by the Dutch Federation of UMCs and the Dutch Government. Besides the multicenter 
collaboration, the multidisciplinary nature of this biobank – involving Gastroenterology, Genetics and 
 Surgery – is essential for its functionality and value.
Patients at increased risk of hereditary CRC and/or Polyposis, or with a proven germline mutation 
 causing CRC and/or Polyposis are included. Both clinical data (demographic data, details on medical and 
family history, information on surveillance, endoscopy and surgery, results of microsatellite instability and 
molecular genetic tests) and biomaterial (DNA, plasma, serum and tissue) are collected in a standardized 
manner.
Keywords: Clinical biobanking; Parelsnoer Institute; hereditary colorectal cancer; harmonized standards; 
research standards
(1) Bioresource Overview
Project description
The Biobank Hereditary colorectal cancer (CRC) was 
established in 2009 with the aim to enable researchers 
to gain a better insight into the genetic factors contrib-
uting to the development of CRC, and ultimately, disease 
prevention. In addition, future research will improve the 
quality and efficiency of care of individuals with heredi-
tary CRC.
Participants are 1) diagnosed with a germline mutation 
that causes CRC and/or Polyposis (e.g. APC, MLH1, MSH2, 
MSH6 or MUTYH) (‘affected’) or 2) are at an increased risk 
of hereditary CRC and/or Polyposis (‘unaffected’). Patients 
diagnosed with CRC before the age of 70 years, diagnosed 
with an adenoma before the age of 40 years, diagnosed 
with cumulative more than 10 adenomas, diagnosed with 
polyposis or diagnosed with CRC and/or adenoma with 
a germline mutation present in the family for hereditary 
CRC and/or Polyposis are considered to have an increased 
risk of hereditary CRC and/or Polyposis. Both clinical data 
(demographic data, details on medical and family his-
tory plus endoscopy and surgery, results of microsatellite 
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instability and molecular genetic tests) and biomaterial 
(DNA, plasma and serum plus both unaffected colorectal 
tissue and affected colorectal tissue, i.e. adenoma or carci-
noma) are collected in a standardized way.
The Biobank Hereditary CRC is part of the Parelsnoer 
Institute (PSI; [1]), which is a unique nationally representa-
tive biobanking partnership between the eight University 
Medical Centers (UMCs) in the Netherlands. As such the 
Biobank Hereditary CRC is embedded in a mature national 
infrastructure for biobanks.
Classification (1)
Human.
Species
Homo sapiens.
Classification (2)
Clinical biobank: biological samples and associated data, 
clinical data.
Context
Spatial coverage
All eight University Medical Centers across the Netherlands: 
Academic Medical Center (Amsterdam), Erasmus Medical 
Center (Rotterdam), Leiden University Medical Center, 
Maastricht University Medical Center, Radboud University 
Medical Center (Nijmegen), University Medical Center 
Groningen, University Medical Center Utrecht, VU 
University Medical Center (Amsterdam).
Northern boundary: +53.4647366.
Southern boundary: +50.757197.
Eastern boundary: +7.222824.
Western boundary: +3.364563.
Temporal coverage
Start data: 2009. End date: not applicable. The intention 
is to include patients as long as possible, which implies 
that biomaterial and associated data will be stored with-
out time limitations.
Temporal coverage for accessibility
N/A.
The Biobank Hereditary CRC has not indicated a date 
when it has to be destroyed.
(2) Methods
Steps
Eligible individuals for the Biobank Hereditary CRC are 
included at three different departments: the depart-
ments of Human Genetics, Surgery or Gastroenterology. 
Individuals are considered to be eligible when they have 
been diagnosed with a germline mutation that causes CRC 
and/or Polyposis, diagnosed with CRC before the age of 
70 years or with an adenoma before the age of 40 years, 
diagnosed with cumulative more than 10 adenomas, 
diagnosed with polyposis, diagnosed with CRC and/or 
adenoma with a germline mutation present in the family 
for hereditary CRC and/or Polyposis. Patients are recruited 
and consented in one of the participating UMC’s by a clini-
cian or a research nurse. Standard operating procedures 
(SOPs) are in place to cover the consent and withdrawal 
process.
Each department collects biomaterials in a uniform way 
and in a routine clinical care setting.
Tissue from a surgical procedure or colonoscopy will 
be stored as frozen or Formalin-Fixed Paraffin-Embedded 
(FFPE) material. Tissue samples are processed by trained 
and certified staff through the UMC histology depart-
ments and only surplus material is passed to the Biobank 
Hereditary CRC. Some participants will visit the UMC 
more often, e.g. for endoscopy surveillance. For these 
participants, follow-up data will be collected and sam-
ples of plasma, serum and tissue will be stored with a 
maximum of twice a year in order to reduce the bur-
den. This will be the first two visits in a year because it 
is not possible to determine in advance which event is 
important.
Sample handling and storage are based on SOPs. These 
procedures were established by PSI to ensure standardized 
sample collection and handling, and to guarantee a col-
lection of samples of high and reproducible quality [1]. 
Deviations from the SOPs are recorded using predefined 
categories which include: issues with haemolytic, lipemic, 
icteric, wrong tube, incorrect volume collected, storage 
temperature deviation, longer storage time, incorrect mix-
ing/homogenization, different centrifugation process, 
storage problem or other deviation as free text. Figure 1 
shows the schematic workflow of the Biobank Hereditary 
CRC. The biomaterial is stored at each participating UMC. 
Note: this is a general workflow that can deviate in the 
different participating UMCs, depending on the local 
workflows.
Stabilization/preservation
Table 1 gives an overview of procedures for collecting, 
processing and storing of samples defined in the Biobank 
Hereditary CRC’s biomaterial protocol.
Type of long-term preservation
See Table 1.
Storage temperature
See Table 1.
Shipping temperature from patient/source to 
preservation or research use
Body fluids (DNA, plasma, serum) from the clinical depart-
ments are transferred by the internal clinical transport 
service of each UMC to the Front Office of the laboratory 
that is responsible for the sample handling.
Fresh frozen and FFPE tissue are directly transferred 
from the operating rooms to the Department of Pathology 
by the internal clinical transport service of each UMC. The 
tissue should be sent in a good leak-proof, unadorned con-
tainer with formalin. The volume of formalin should be at 
least twice as large as the tissue fragment. Until transport, 
tissue can best be stored at 4°C (refrigerator) or briefly at 
room temperature and not in (melting) ice.
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Figure 1: The flow of biomaterial and associated clinical data of the Biobank Hereditary CRC.
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Table 1: Overview of procedures on collection, processing and storage of samples defined in the Biobank Hereditary 
CRC’s biomaterial protocol.
Sample Volume/number Processing Time between 
 sampling and 
storage
Aliquoting Storage
DNA (blood) 6 ml EDTA blood Standard DNA isolation from 
EDTA in clinical routine of the 
Department of Human Genetics
Within 4 weeks 
(4°C) or 3 
months (<–20°C)
Stock solution, after 
first issuance: normal-
ized fraction 100 ng/μL
–20°C
Serum 10 ml, addition of 
a clot activator
2,000 × g at room temperature 
for 10 minutes
Within 2–4 
hours
Maximum of six 
 aliquots (0.5 ml)
–80°C
EDTA 
plasma
10 ml 2,000 × g at room temperature 
for 10 minutes
Within 2–4 
hours
Maximum of six 
 aliquots (0.5 ml)
–80°C
Fresh frozen 
tissue
Sample of affected 
and unaffected 
tissue
Immediately frozen after collect-
ing the sample
Immediate 0.5 cm3 samples –80°C
FFPE tissue1 Sample of affected 
and unaffected 
tissue
Immediately stored in formalin 
after collecting the sample (0.5 
cm3), afterwards embedded in 
paraffin
Immediate 
fixation
0.5 cm3 samples Room 
 temperature
1 FFPE = Formalin-Fixed Paraffin-Embedded.
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Shipping temperature from storage to research use
Body fluids, or materials and fresh frozen tissue samples 
are shipped on an excess of dry ice (–80°C) and FFPE sam-
ples at room temperature. Shipment is carried out by vari-
ous certified courier services. At the moment, data loggers 
are not used. However, each confirmation of receipt of a 
shipment attests that sufficient dry ice was still present in 
the package.
Quality assurance measures
The sample handling is embedded in the quality manage-
ment system of all cooperating UMC’s [1]. Process control 
is based on SOPs that cover all phases of biobanking: col-
lection, pre-analysis, registration, processing and storage 
of the samples.
Source of associated data
For the Biobank Hereditary CRC a minimal dataset was 
defined. This dataset comprises patient information collected 
in the context of routine daily clinical practice (Table 2). 
At baseline clinical data is collected on demographic data, 
details on medical and family history plus endoscopy and 
surgery, results of microsatellite instability and molecular 
genetic tests. During the follow-up, data is obtained on the 
treatment of the patient. Furthermore, in order to facilitate 
complete follow-up information on all included patients, 
connections to existing medical registries are actively sought 
(e.g. links to registries for vital status, cause of death, cancer 
diagnoses and pathology records).
The Biobank Hereditary CRC guarantees the privacy of 
the participants, because both biomaterial and the associ-
ated clinical data are stored using unique codes.
As described by Manniën et al., the information supplied 
by each UMC is periodically uploaded, after validation, 
to the central database of PSI for storage on a national 
level [1]. During the upload of data to central database, a 
Trusted Third Party encrypts identifiers of each UMC.
Ethics Statement
In 2009, the local Research Ethics Committees (RECs) 
of all UMCs have approved the initiation of the Biobank 
Hereditary CRC. Each research proposal that includes the 
use of biomaterial and/or clinical data of the Biobank 
Hereditary CRC must be submitted to the scientific review 
committee of the Biobank Hereditary CRC. This commit-
tee will decide whether a protocol is relevant and valid. 
As a next step, the research proposal has to be approved 
by the REC or a formal Institutional Review Board (IRB). 
These committees will assess whether the study objec-
tive fits the scope of the Biobank Hereditary CRC and its 
informed consent procedure.
Eligible patients are invited to participate in the 
Biobank Hereditary CRC, and sign the informed consent 
after understanding the goals of the biobank. SOPs are in 
place to cover the consent and withdrawal process.
Constraints
Geographical: the Biobank Hereditary CRC collects biomate-
rial primarily collected at UMCs, tertiary care hospitals. Only 
patients who provided written informed consent are included. 
Participants may withdraw their consent at all times.
(3) Bioresource description
Object name
The Biobank Hereditary CRC.
Bioresource name
The Biobank Hereditary CRC.
Bioresource location
All eight UMCs across the Netherlands participate in PSI:
 – Academic Medical Center, Meibergdreef 9, 1105 AZ 
Amsterdam, The Netherlands
 – Erasmus Medical Center, ’s-Gravendijkwal 230, 3015 
CE Rotterdam, The Netherlands
 – Leiden University Medical Center, Albinusdreef 2, 
2333 ZA Leiden, The Netherlands
 – Maastricht University Medical Center, P. Debyelaan 
25, 6229 HX Maastricht, The Netherlands
 – Radboud university medical center, Geert Groot-
eplein-Zuid 10, 6525 GA Nijmegen, The Netherlands
 – University Medical Center Groningen, Hanzeplein 1, 
9713 GZ Groningen, The Netherlands
 – University Medical Center Utrecht, Heidelberglaan 
100, 3584 CX Utrecht, The Netherlands
 – VU University Medical Center, De Boelelaan 1117, 
1081 HV Amsterdam, The Netherlands
Bioresource contact
Peggy Manders, Geert Grooteplein-Zuid 10, 6525 GA 
Nijmegen, The Netherlands.
Email: peggy.manders@radboudumc.nl
Bioresource URL
h t t p : / / w w w. p a r e l s n o e r . o r g / p a g e / e n / Pa r e l s ? 
mod[Parelsnoer_Module_Pearl][n]=25
Identifier used
N/A
Bioresource type
The Biobank Hereditary CRC Radboud Biobank is a col-
laborative clinical biobank. It stores biomaterials (see 
Table 1) and clinical data (Table 2) of individuals with 
an increased risk of hereditary CRC and/or Polyposis or 
diagnosed with a gene mutation which causes CRC and/or 
Polyposis and achieves almost total population coverage 
because the larger part is seen in a UMC.
Type of sampling
The Biobank Hereditary CRC is a biobank that combines 
both ‘affected’ individuals diagnosed with a gene mutation 
that predisposes to CRC and/or Polyposis (e.g. APC, MLH1, 
MSH2, MSH6 or MUTYH) and ‘unaffected’ individuals at 
increased risk of hereditary CRC and/or Polyposis (i.e diag-
nosed with a CRC or adenoma at a relatively young age).
Anatomical site
See Table 3.
Disease status of patients/source
See Table 3.
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Table 2: Overview of patient information collected in the context of the Biobank Hereditary CRC.
Data category1 Items1
General information of the 
patient
Identifier
Date of birth
Gender
Date of inclusion
Patient category
Ethnicity/race
Date of death
Autopsy has been performed
Cause of death
Information on medical 
 history of the patient
Date of consult
No previous surgery or admission to a hospital
CRC
CRC – date of diagnosis
Diagnosis of CRC – based on complaints
Diagnosis of CRC – based on surveillance CRC
Year of start surveillance CRC
Type of surveillance used at diagnosis of CRC
Date of penultimate surveillance
Additional remarks regarding CRC in general
Adenomas
Adenomas – date of diagnosis
Colitis Ulcerosa/M. Crohn
Colitis Ulcerosa/M. Crohn – date of diagnosis
Date of first visit to a hospital
Above 10 adenomas (cumulative)
Date of diagnosis of 10th adenoma
Above 10 polyps unlike adenoma
Date of diagnosis of 10th polyp unlike adenoma
Cancer unlike CRC
Cancer unlike CRC – date of diagnosis
Additional remarks regarding medical history
Intoxication Smoker’s category
Type of tobacco
Amount of cigarettes per day
Year of start smoking
Last year of stop smoking
Passive smoker
Physical examination Height (cm)
Current weight (kg)
Weight at endoscopy (kg)
Weight at surgery (kg)
Highest weight (excl. pregnancy – kg)
Year of highest weight
Information on first 
degree family members of 
the patient
Relationship between first degree family member and patient
Year of birth of first degree family member
Date of inquiry of medical history of first degree family member
Medical history of first degree family member
Age at diagnosis of first degree family member
Date of death of first degree family member
First degree family member participant of biobank
Genetic testing Genetic testing started in family
Year of start genetic testing
Genetics center
Germline mutation present (patient or family)
Gene with germline mutation
Name of germline mutation
Is the patient a mutation carrier
Year of diagnosis germline mutation – patient
Molecular diagnostics on colorectal related material
Microsatellite instability present
(Contd.)
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Data category1 Items1
IHC MLH1
IHC MSH2
IHC MSH6
IHC PMS2
Hypermethylation
Additional remarks regarding molecular diagnostics – other
Endoscopic examination Endoscopy
Date of endoscopy
Type of endoscopy
Indication for endoscopy
Total number of polyps (endoscopy)
Location of endoscopy
Number of polyps per location (endoscopy)
Lesion – endoscopy
(>10 polyps, registration 
of additional information)
Polyp number
Location of lesion
Distance between lesion and anus (cm – stretched endoscope)
Size of lesion (mm – endoscopy)
Form of lesion
Type of lesion (macroscopic – endoscopy)
Radically removed (macroscopic – endoscopy)
Treatment of lesion (endoscopy)
Surgery Surgery
Date of surgery
Type of surgery
Location of the tumor
Location of distant metastasis
Stoma
Stoma – temporary or permanent
Preoperative radiotherapy
Date of start preoperative radiotherapy
Total dose of preoperative radiotherapy (gray – cumulative)
Total of preoperative radiotherapy fractions
Preoperative chemotherapy
Type of preoperative chemotherapy
Date of start preoperative chemotherapy
Total of preoperative chemotherapy cycles
Pathology Histology
Histological grade
Tumor size (pT)
Number of removed lymph nodes – surgery
Number of positive lymph nodes – surgery
Number of removed polyps/adenomas – surgery
Location of regional metastasis
Lymphocytic infiltration
Adenoma (surgery)
Location per adenoma (surgery)
Number of adenomas (surgery)
Size of largest adenoma (mm – surgery)
Location largest adenoma (surgery)
Hyperplastic polyps (surgery)
Number of hyperplastic polyps (surgery)
Additional remarks regarding tissues removed at surgery
Type of removed material – endoscopy
Type of lesion
Type of adenoma
Type of dysplasia (adenoma)
Data on biomaterial Collecting time
Specimen type
Sample code
Storage type
(Contd.)
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Clinical characteristics of patients/source
A full clinical characterization, including demographic 
data, details on medical and family history plus endos-
copy and surgery, results of microsatellite instability and 
molecular genetic tests and follow-up is specified for the 
Biobank Hereditary CRC (Table 2).
Vital state of patients/source
All patients are alive at inclusion.
Size of the bioresource
Currently, the Biobank Hereditary CRC contains differ-
ent biomaterials (e.g. DNA, plasma, serum and/or tissue) 
from 1,967 participants. The current number of included 
patients per patient category is shown in Table 3.
Clinical diagnosis of patients/source
See Table 3.
Pathology diagnosis
Colorectal carcinoma and adenoma.
Control samples
The Biobank Hereditary CRC does not collect control 
samples from individuals without a proven CRC and/or 
Polyposis related germline mutation or who are not at an 
increased risk of hereditary CRC and/or Polyposis.
Biospecimen type
Table 1 summarizes the variety of biomaterials that can be 
collected per participant of the Biobank Hereditary CRC. 
However, the specific collection of the biomaterials depends 
on the patient category, e.g. tissue will only be collected of 
the patients who have been diagnosed with CRC and were 
surgically treated in one of the participating UMCs.
Release date
Biomaterial and the matching clinical data are currently 
available.
Access criteria
Scientific researchers, who are not necessarily linked to the 
Biobank Hereditary CRC, but who are working in the field of 
Data category1 Items1
Tissue status
Biopsy location
Carcinoma location
Collection method
Amount of tissue
DNA concentration
DNA quality
SOP respected?
SOP deviation
Other SOP deviation
CRC = colorectal cancer.
1 Not all data is available for all patients.
Table 3: Overview of the categories of participants that can be included in the Biobank Hereditary CRC.
Patient 
Category1
Description Number of included 
participants1
1 Patient with CRC diagnosed before the age of 70 years 1,120
2 Patient with CRC with a germline mutation present in the family for hereditary 
CRC or polyposis
97
3 Patient with an adenoma diagnosed before the age of 40 years 167
4 Patient with an adenoma with a germline mutation present in the family for 
hereditary CRC or polyposis
214
5 Patient with polyposis (FAP, AFAP, MAP, juvenile polyposis) 243
6 Patient with cumulative more than 10 adenomas 178
7 Patient with other polyposis syndrome than described in category 5
(e.g. Peutz Jeghers, PTEN Hamartome Tumour Syndrome)
133
8 Patient with CRC and a germline mutation for hereditary CRC or polyposis 141
9 Healthy individual with a germline mutation for hereditary CRC or polyposis 374
10 Patient with an adenoma and a germline mutation for hereditary CRC or polyposis 211
CRC = colorectal cancer.
1 A participant can appear in more than one category.
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hereditary CRC are invited to submit their research propos-
als. In the catalog of PSI [1] a researcher can identify which 
items are collected by the latter biobank. Each new study 
proposal should be sent to the coordinator of the Biobank 
Hereditary CRC (i.e. currently dr. P. Manders; Radboudumc, 
The Netherlands). The coordinator will submit the proposal 
to the scientific review committee of the Biobank Hereditary 
CRC. This committee, which consists of one member of each 
participating UMC, will review every application on the fol-
lowing criteria: the anticipated significance of the research 
for hereditary forms of CRC and thus the patients included 
in the Biobank Hereditary CRC, plus scientific quality, nov-
elty, feasibility and the suitability. The review process for 
rare patient groups is less strict for requests for data usage 
than requests for biomaterial groups, because of the finite 
nature of the biomaterial. The researcher will be informed 
in writing about the decision of the latter committee by 
the coordinator. As a next step, the research proposal has 
to be approved by the REC or a formal IRB. These commit-
tees will assess whether the study objective fits the scope of 
the Biobank Hereditary CRC and its informed consent pro-
cedure. The aim of the Biobank Hereditary CRC is to make 
the whole issuance process as simple and transparent as 
possible for researchers. Therefore, the coordinator of the 
Biobank Hereditary CRC acts as a contact for researchers 
throughout the complete issuance process.
Costs vary depending on the type and amount of sam-
ples. An economic quotation is sent covering shipping 
costs and partially costs for biobanking-related services 
(sample handling, consumables) [1].
(4) Reuse potential
Biomaterial and clinical data are provided to researchers on a 
non-exclusive basis. Therefore samples from the same partici-
pant may be used in several different projects. However, each 
research project must be approved by the scientific review 
committee of the Biobank Hereditary CRC and by the REC 
or a formal IRB. A prerequisite for the delivery of biomaterial 
and clinical data is two-way data sharing. Which implies that 
new information becomes available from scientific analyses, 
will be added to the Biobank Hereditary CRC database.
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